Key facts
- This page summarizes TAKEDA PHARMACEUTICAL CO LTD's Form 4 filing for Day One Biopharmaceuticals, Inc. (DAWN).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Dec 2021, 05:04.
TAKEDA PHARMACEUTICAL CO LTD - 07 Dec 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- DAWN
- Reported as of
- 07 Dec 2021
- Net transaction value
- -$5,496,869
- SEC form
- 4
- Accepted by SEC
- 09 Dec 2021, 05:04:25 UTC
- Prior SEC filing
- 07 Dec 2021
- Next SEC filing
- 16 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
TAKEDA PHARMACEUTICAL CO LTD filed Form 4 for Day One Biopharmaceuticals, Inc. (DAWN) on 09 Dec 2021.
Change
- Previous filing in this sequence was filed on 07 Dec 2021.
- Current net transaction value: -$5,496,869.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DAWN
transaction
Common Stock
Sale
- Transaction value
- $2,372,770
- Shares
- -128,745
- Change %
- -2%
- Price
- $18.43
- Shares after
- 6,288,652
- Date
- 07 Dec 2021
- Ownership
- See Explanation of Responses
- Footnotes
- F1, F2, F3, F4
DAWN
transaction
Common Stock
Sale
- Transaction value
- $1,134,705
- Shares
- -58,190
- Change %
- -0.93%
- Price
- $19.50
- Shares after
- 6,230,462
- Date
- 07 Dec 2021
- Ownership
- See Explanation of Responses
- Footnotes
- F2, F3, F4, F5
DAWN
transaction
Common Stock
Sale
- Transaction value
- $1,989,394
- Shares
- -110,338
- Change %
- -1.8%
- Price
- $18.03
- Shares after
- 6,120,124
- Date
- 08 Dec 2021
- Ownership
- See Explanation of Responses
- Footnotes
- F2, F3, F4, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
TAKEDA PHARMACEUTICAL CO LTD is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
Footnote F2
This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc.
Footnote F3
Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%).
Footnote F4
Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein.
Footnote F5
Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $19.00 to $19.88. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
Footnote F6
Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.47. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.